Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/127493
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Structural and Kinetic Characterization of Thymidine Kinase from Leishmania major

AutorTimm, Jennifer; Bosch-Navarrete, Cristina; Recio, Eliseo; Nettleship, Joanne E.; Rada, Heather; González-Pacanowska, Dolores; Wilson, K. S.
Fecha de publicaciónmay-2015
EditorPublic Library of Science
CitaciónPLoS Neglected Tropical Diseases
ResumenLeishmania spp. is a protozoan parasite and the causative agent of leishmaniasis. Thymidine kinase (TK) catalyses the transfer of the γ-phosphate of ATP to 2’-deoxythymidine (dThd) forming thymidine monophosphate (dTMP). L. major Type II TK (LmTK) has been previously shown to be important for infectivity of the parasite and therefore has potential as a drug target for anti-leishmanial therapy. In this study, we determined the enzymatic properties and the 3D structures of holo forms of the enzyme. LmTK efficiently phosphorylates dThd and dUrd and has high structural homology to TKs from other species. However, it significantly differs in its kinetic properties from Trypanosoma brucei TK since purines are not substrates of the enzyme and dNTPs such as dUTP inhibit LmTK. The enzyme had Km and kcat values for dThd of 1.1 μM and 2.62 s-1 and exhibits cooperative binding for ATP. Additionally, we show that the anti-retroviral prodrug zidovudine (3-azido-3-deoxythymidine, AZT) and 5’-modified dUrd can be readily phosphorylated by LmTK. The production of recombinant enzyme at a level suitable for structural studies was achieved by the construction of C-terminal truncated versions of the enzyme and the use of a baculoviral expression system. The structures of the catalytic core of LmTK in complex with dThd, the negative feedback regulator dTTP and the bi-substrate analogue AP5dT, were determined to 2.74, 3.00 and 2.40 Å, respectively, and provide the structural basis for exclusion of purines and dNTP inhibition. The results will aid the process of rational drug design with LmTK as a potential target for anti-leishmanial drugs.
Versión del editorhttp://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003781
URIhttp://hdl.handle.net/10261/127493
DOI10.1371/journal.pntd.0003781
E-ISSN1935-2727
Aparece en las colecciones: (IPBLN) Artículos

Ficheros en este ítem:
Fichero Descripción Tamaño Formato
journal.pntd.0003781.pdf3,8 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

5
checked on 01-abr-2024

SCOPUSTM   
Citations

13
checked on 23-abr-2024

WEB OF SCIENCETM
Citations

11
checked on 28-feb-2024

Page view(s)

219
checked on 23-abr-2024

Download(s)

242
checked on 23-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.